82% of participants in the corticosteroid arm elected to...

• 82% of participants in the corticosteroid arm elected to crossover to OrthoATITM and experienced almost complete resolution of pain 6 months post-treatment, which was sustained at 12 months

• Results in the crossover group mirrored those of the original OrthoATITM group, which showed clinically

  and statistically significant improvements in shoulder pain and function
  
  Hmm, 82% started with corticosteroid injection then crossed over to Ortho ATI.....so should we assume the same % with the 4 -5 billion in annual US sales eventually? Unless something superior turns up I assume yes!

  1. US company Vericel, which currently generates more than $120 million in sales and is only used to treat one target joint in the body. Vericel currently has a market capitalisation of approximately $1.2 billion.
     
     So based on the above should we also assume the value of OCC should be 80% odd of 40-50 billion if they get anywhere near 4-5 billion in sales?
     
     Plenty of forward opportunity in this stock....it has to be one of the most underrated stocks for what the IP they have! Patience will be the winner with this one!